Stress has long been felt in the body as a weight carried through sleepless nights and tense days, yet its reach into illness has been harder to trace. A team at West China Hospital of Stomatology in Sichuan now describes a route through which persistent distress may quicken the growth of oral cancer: from the brain's hypothalamus to the pituitary gland, and onward to the bone marrow, where immune cells meant to police tumors are instead turned toward silence. The findings, drawn from patient records, tissue samples and laboratory mice, remain a careful signal rather than a settled verdict, si
Chronic Stress Drives Oral Cancer Through a Brain-to-Immune Pathway, Study Finds
Chronic stress was linked to worse survival and higher head and neck cancer mortality among UK Biobank participants with anxiety or depression.
An active biological driver of oral cancer, not only a psychological burden
Mark
What's the core finding here?
Mimi
That stress isn't just correlated with worse oral cancer outcomes. In mice, researchers traced a chain: brain, pituitary, α-MSH, bone marrow suppressor cells, weakened T cells, faster tumors.
Mark
And the human side?
Mimi
In the UK Biobank, anxiety and depression were independently linked to higher head and neck cancer mortality. Patient serum α-MSH rose from normal tissue to leukoplakia to carcinoma.
Luke
But the Biobank measured stress once. The authors themselves say causality can't be established in people.
Mimi
Right. The human data show association; the mechanism comes from mice.
Mark
Why does the precancer finding matter?
Mimi
The authors say the axis seems engaged even at the leukoplakia stage, which hints at early markers, though that needs validation.
Luke
The drug result is also mouse-only. We don't know the right dose, or whether it works in patients.
Mark
So what would change practice?
Mimi
Trials testing α-MSH and LOX-1 as biomarkers, and testing the receptor blocker with PD-1 therapy.
Luke
Until then, the suggestion to screen for anxiety and depression is a proposal, not a proven intervention.
O Pulso
- Chronic stress appears to push a hormone signal from the brain all the way to the bone marrow, where it multiplies immune cells that quiet the body's attack on tumors.
- In patients, the same suppressive cells climb steadily from healthy tissue to precancerous lesions to full oral cancer, raising alarm about how early the damage begins.
- Researchers are testing whether blocking a single receptor can restore tumor-fighting T cells and make existing immunotherapy work better in mice.
- The combination showed promise in animals, but the human link is still only an association, and clinical trials must now confirm whether these markers and treatments hold in people.
Stress has long been felt in the body as a weight carried through sleepless nights and tense days, yet its reach into illness has been harder to trace. A team at West China Hospital of Stomatology in Sichuan now describes a route through which persistent distress may quicken the growth of oral cancer: from the brain's hypothalamus to the pituitary gland, and onward to the bone marrow, where immune cells meant to police tumors are instead turned toward silence. The findings, drawn from patient records, tissue samples and laboratory mice, remain a careful signal rather than a settled verdict, since the human evidence shows association and the mechanism has so far been observed chiefly in animals. Still, the work invites a larger reckoning with the idea that a troubled mind and a failing defense may be more closely bound than medicine has usually allowed.
A team at West China Hospital of Stomatology, Sichuan University, has been following a question that many clinicians have sensed but few could trace: how chronic psychological stress might help oral cancer grow. Their findings, published in the International Journal of Oral Science, describe a pathway that runs from the brain to the pituitary gland and then to the bone marrow, ending in the immune cells that should be fighting tumors.
The human evidence came first. Among participants in the UK Biobank, people with anxiety or depression faced higher mortality from head and neck squamous cell carcinoma, and those under chronic stress had noticeably worse overall survival. In patient samples, a hormone called α-MSH and a marker of suppressive immune cells rose together, step by step, from healthy mucosa to precancerous lesions to full cancer.
In mice, the researchers watched the mechanism unfold. Prolonged restraint stress raised α-MSH, which expanded a population of suppressor cells in the bone marrow. These cells muted the CD8+ T cells that attack tumors, and the tumors grew faster and returned more often after surgery. Neutralizing a chemical signal called CXCL13 eased the effect, restoring T cell activity and slowing growth.
The team then tried to break the circuit itself. Blocking the melanocortin 1 receptor, combined with anti-PD-1 immunotherapy, produced the smallest tumors and the strongest immune response in mice, without obvious toxicity. Because immunotherapy often works poorly in this cancer, that combination is offered as a hopeful direction.
The authors are careful about limits. The UK Biobank measured stress only once, so cause cannot be proven, and much of the mechanism remains in animals. Should the pathway hold in patients, blood markers and routine screening for anxiety and depression might one day help identify who needs closer watch. For now, the work is an invitation to study the body and mind as one connected system.
A team at West China Hospital of Stomatology, Sichuan University, has traced a path by which chronic psychological stress may speed the growth of oral cancer. Their report, published in the International Journal of Oral Science (DOI: 10.1038/s41368-026-00468-x), describes a circuit running from the brain to the pituitary gland to the bone marrow, and from there to the immune cells that are supposed to fight tumors.
The question they set out to answer has been open for some time. Chronic stress is increasingly recognized as a risk factor for cancer, yet how the central nervous system carries that influence to the immune system has remained unclear. The researchers define chronic stress as a persistent adaptive response that the nervous system mounts after exposure to stressors, often showing up as anxiety or depression. They focused on oral squamous cell carcinoma, and they drew on several kinds of evidence: the UK Biobank cohort, serum and tissue samples from patients, and mouse models covering chemical carcinogenesis, orthotopic tongue tumors and recurrence after surgery.
The human data came first. In the UK Biobank analysis, anxiety and depression were each independently associated with higher mortality from head and neck squamous cell carcinoma, and chronically stressed patients had significantly worse overall survival. In patient samples, serum levels of α-melanocyte-stimulating hormone (α-MSH) rose step by step from normal mucosa to oral leukoplakia to oral squamous cell carcinoma. So did LOX-1, a marker of human polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), and the two were strongly correlated.
The mouse experiments laid out the mechanism. Chronic restraint stress activated neurons in the hypothalamic paraventricular nucleus and increased production of proopiomelanocortin (POMC) in the intermediate lobe of the pituitary. Serum α-MSH climbed, PMN-MDSCs expanded in the bone marrow, and tumors grew faster. These suppressor cells blunt CD8+ T cells, the immune cells that attack tumors. RNA sequencing pointed to a chemokine called CXCL13 as a key stress-induced signal; neutralizing it reduced PMN-MDSC accumulation, restored CD8+ T cell infiltration and slowed tumor growth. Stress also worsened recurrence after surgery.
Tissue microarrays from patients echoed the pattern. LOX-1-positive PMN-MDSCs increased with clinical stage, tracked with CD68+CD206+ M2 macrophages, inversely correlated with CD8+ T cells and predicted poorer survival.
The team then tested whether the circuit could be interrupted. An inhibitor of the melanocortin 1 receptor, JNJ-10229570, was combined with anti-PD-1 therapy in mice. That pairing produced the smallest tumors and the greatest CD8+ T cell infiltration while suppressing PMN-MDSCs, with no overt toxicity. The blocker also eased the weight loss associated with anti-PD-1 treatment. The authors note that response rates to PD-1 and PD-L1 blockade in oral squamous cell carcinoma are low, and they see combination approaches as a way to improve them.
The authors argue the work recasts chronic stress as an active biological driver of oral cancer rather than only a psychological burden. They say the axis appears to engage early, even at the precancerous stage, and that its activation reprograms the tumor microenvironment toward immunosuppression.
There is a stated limit. The UK Biobank assessed stress at a single time point, so causality cannot be established, and the authors say further studies are needed to validate the pathway in patients. Much of the mechanistic work is also in mice.
If it holds up, circulating α-MSH and LOX-1-positive PMN-MDSC density could serve as minimally invasive biomarkers for patients at higher risk of progression or relapse, and routine screening for anxiety and depressive symptoms might flag people needing closer follow-up. The authors call for work on dosing, predictive biomarkers and combinations with other immunomodulators in clinical trials.
Citações Notáveis
Chronic stress is an active biological driver of oral cancer rather than a purely psychological burden.— Study authors, West China Hospital of Stomatology
Single-time-point stress assessments in the UK Biobank mean causality cannot be established.— Study authors
Quer a matéria completa?
Leia o original em News-Medical ↗